GlassScriptPhysician profile
Steven W Yates
NPI 1609814417
$3,453.88
in general payments reported to CMS, 2019-2025
18 companies · $99.99 in 2025
The $99.99 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $255 · 2021: $627 · 2022: $324 · 2023: $325 · 2024: $1,601 · 2025: $99.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $957 · Food and Beverage: $936 · Education: $99.99 · Gift: $33.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $957.29 |
| Food and Beverage | $936.28 |
| Education | $99.99 |
| Gift | $33.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Oncology Corporate, INC. | $1,392.39 | 2024 | |
| Cardinal Health 108 LLC | $468.02 | 2019-2024 | |
| Genzyme Corporation | $268.22 | 2021-2022 | |
| Emd Serono, INC. | $230.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $149.76 | 2021 | |
| Karyopharm Therapeutics INC. | $124.52 | 2023 | Xpovio |
| Verastem, INC. | $124.28 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $121.81 | 2023 | Imfinzi |
| Astellas Pharma US INC | $99.99 | 2025 | |
| Amgen INC. | $95.00 | 2020 | |
| Kite Pharma, INC. | $94.78 | 2021 | |
| Pfizer INC. | $83.09 | 2024 | |
| Abbvie INC. | $77.71 | 2020-2023 | Venclexta |
| Glaxosmithkline, LLC. | $33.52 | 2021 | |
| Daiichi Sankyo INC. | $29.44 | 2023 | Enhertu |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $21.51 | 2023 | Tukysa |
| Novartis Pharmaceuticals Corporation | $21.33 | 2019 | |
| Celgene Corporation | $18.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Yates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.